Company news

Immunic, Inc. news in 2022

Immunic, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential

November 16, 2022

Immunic, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 2, 2022

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update

October 26, 2022

Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate

October 19, 2022

Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing

October 9, 2022

Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects

September 19, 2022

Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium

August 15, 2022

Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 3, 2022

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update

July 27, 2022

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén

July 5, 2022

Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology

June 14, 2022

Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June

June 7, 2022

Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update

June 1, 2022

Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 9, 2022

Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease

May 4, 2022

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate Update

May 2, 2022

Immunic, Inc. Announces Promotion of Glenn Whaley, CPA to Chief Financial Officer

March 15, 2022

Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity

February 23, 2022

Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Co...

February 17, 2022

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update

February 16, 2022

Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor

February 1, 2022

Calls in 2022

Decks in 2022